Guggenheim analyst Yatin Suneja downgraded Regeneron Pharmaceuticals to Neutral after taking over coverage of the name, citing his belief that growth in its flagship Eylea product is abating and the launch of competitive products and biosimilars could lead to pricing pressure. The analyst lowered the price target for the shares to $425 from the firm’s prior $466 target.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.